Menu
Not yet recruiting NCT07519317

Dosing and Deployment Trial: A Home-based Optokinetic Treatment

No phase Interventional Spatial Neglect

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Optokinetic stimulation.
Who it may be relevant to
Registry conditions: Spatial Neglect. Basic parameters: 60 years — 110 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Dosing and Deployment Trial: A Home-based Optokinetic Treatment for Ipsilesional Gaze Deviation

Overview

Several interventions exist for remediation of spatial neglect, but they have mixed evidence. Optokinetic stimulation is a bottom-up intervention; in other words, it is a stimulus-driven process, with Level A (strongest) evidence, and is recommended in clinical practice guidelines such as the American Heart Association's stroke guidelines. The studies currently published all use varing doses (number of sessions a week), did not assess the impact on mobility and risk of falls, and have not been implemented in the home setting. It is imperative to understand how to successfully implement this intervention at home, and learn how it will impact mobility in order to better support a large population of individuals living with chronic spatial neglect and who face barriers to accessing care because they require caregiver support to leave the home. This will be done using both qualitative and quantitative methods.

Detailed description

Stroke is a leading cause of disability among adults in the United States (US) and increases the risk of falls. One factor associated with excess fall risk after stroke is spatial neglect, which occurs in 54% of right brain damaged stroke survivors. Spatial neglect is caused by damaged neural networks critical for spatial attention. A hallmark symptom of spatial neglect is ipsilesional gaze deviation (IGD) , which is a sustained horizontal gaze preference toward the affected brain hemisphere. Since IGD is a major predictor of poor recovery-adversely affecting daily activities and functional mobility, and extending hospital stays because of falls-intervention is necessary. And because of the challenges of the traditional rehabilitation paradigm (short length of stay), there is a significant need for an intervention, accessible to individuals living at home with SN, that will improve mobility and risk of falls.

Optokinetic stimulation is a treatment shown to induce brain neural plasticity and improve spatial exploration, in turn reduce spatial neglect symptoms, including IGD, experienced in daily life. Optokinetic stimulation requires the participant to follow one step command: "follow the targets with your eyes". The target is a small dot that moves across the computer screen. The literature shows variation in implementation because users (mostly therapists) were required to create their own optokinetic stimulation, until just recently when Eyemove was developed. Eyemove is computer-based intervention developed to standardize the way optokinetic stimulation is administered, via an inexpensive, commercially available software program.

Via a randomized clinical trial, the researchers plan to focus on dose and feasibility in the home setting to answer the specific aims.

The study will randomize stroke participants who meet all inclusion and exclusion criteria into two intervention dose groups. Group 1 will complete 3-sessions of Eyemove, and Group 2 will complete 5-sessions of Eyemove, all within 7-9 days. Outcomes will be measured at baseline, before and after the treated period. Screening and pre-treatment assessments will take approximately 2 hours, and the post assessments will take approximately 1 hour. The post-treatment assessments will be conducted 14 days after the pre-treatment assessments.

In the interest of feasibility and limiting unnecessary burden on participants, the study team will then conduct semi-structured interviews pre-treatment with at least the first 8 stroke participants who are randomized into each group. The study team will interview them again post-treatment and will also interview care partners of stroke survivors at time of screening and pre-treatment assessment, to participate in semi-structured interviews and two assessments. The researchers will also plan to conduct these with the first 8 care partners from each group, which will be determined after the stroke survivor is randomized.

Interventions

  • Behavioral Optokinetic stimulation
    Visual scanning (repeated eye movements) from one side of the computer to the neglected side of space. The target is 30 to 70 dots, randomly displayed (of all colors, size: 2- 4 cm) on a dark background on a computer screen.

Primary outcome measures

  • The Mobility Assessment Course [Time frame: 20 minutes]
Secondary outcome measures (3)
  • Health-ITUES [Time frame: 10 minutes]
  • Stroke Assessment of Fall Risk [Time frame: 10 minutes]
  • Caregiver Burden Scale [Time frame: 10 minutes]

Eligibility criteria

Inclusion Criteria for stroke group:

  • first and unilateral right brain damage stroke, confirmed by medical records,
  • time post stroke >6 months,
  • moderate to severe SN, classified using the Catherine Bergego Scale (CBS) via the Kessler Foundation Neglect Assessment Process (KF-NAP),
  • over age of 60 years, and
  • IGD noted either on the KF-NAP or neuroimaging from medical records.

Exclusion Criteria for stroke group:

  • history of multiple strokes or neurological incidents (e.g., traumatic brain injury, seizures, or brain tumor),
  • unable to communicate through spoken English, screened using the Aphasia Rapid Test (ART), as instructions for treatment and assessment tasks will be provided verbally in English,
  • cognitive impairment as defined by the Blind-MoCA,
  • dependent in mobility- walking or wheelchair via medial chart,
  • legally blind per medical chart,
  • home located out of a 50-mile radius from Duke University, making it too costly for the frequent home visits, and
  • no IGD present.

Inclusion Criteria for caregiver group:

  • a current care partner (defined as someone providing care and assistance) of a stroke survivor living with SN,
  • English speaker,
  • the stroke survivor they are caring for has been enrolled into the study.

Exclusion Criteria for caregiver group:

  • not a care partner currently,
  • can't speak English,
  • the stroke survivor didn't consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07519317 · Pro00118913

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗